Published in Biol Psychiatry on November 14, 2008
Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment. Pharmacol Ther (2011) 1.71
Essential role for orbitofrontal serotonin 1B receptors in obsessive-compulsive disorder-like behavior and serotonin reuptake inhibitor response in mice. Biol Psychiatry (2011) 1.46
Impaired sensorimotor gating in unmedicated adults with obsessive-compulsive disorder. Neuropsychopharmacology (2012) 1.17
Fine mapping of QTL for prepulse inhibition in LG/J and SM/J mice using F(2) and advanced intercross lines. Genes Brain Behav (2010) 1.03
Fluoxetine exerts age-dependent effects on behavior and amygdala neuroplasticity in the rat. PLoS One (2011) 1.01
Genetic models of sensorimotor gating: relevance to neuropsychiatric disorders. Curr Top Behav Neurosci (2012) 0.97
Placental serotonin: implications for the developmental effects of SSRIs and maternal depression. Front Cell Neurosci (2013) 0.97
cGMP-dependent protein kinase Ialpha associates with the antidepressant-sensitive serotonin transporter and dictates rapid modulation of serotonin uptake. Mol Brain (2009) 0.97
Differences in aggressive behavior and DNA copy number variants between BALB/cJ and BALB/cByJ substrains. Behav Genet (2009) 0.96
Assessing the validity of current mouse genetic models of obsessive-compulsive disorder. Behav Pharmacol (2009) 0.96
Anxiety and affective disorder comorbidity related to serotonin and other neurotransmitter systems: obsessive-compulsive disorder as an example of overlapping clinical and genetic heterogeneity. Philos Trans R Soc Lond B Biol Sci (2013) 0.94
5-HT(1B) autoreceptor regulation of serotonin transporter activity in synaptosomes. Synapse (2012) 0.86
Bidirectional regulation of emotional memory by 5-HT1B receptors involves hippocampal p11. Mol Psychiatry (2012) 0.86
Sertraline exposure leads to small left heart syndrome in adult mice. Pediatr Res (2012) 0.85
DISSECTING OCD CIRCUITS: FROM ANIMAL MODELS TO TARGETED TREATMENTS. Depress Anxiety (2015) 0.85
HTR1B as a risk profile maker in psychiatric disorders: a review through motivation and memory. Eur J Clin Pharmacol (2009) 0.83
5-HT1B receptor modulation of the serotonin transporter in vivo: studies using KO mice. Neurochem Int (2013) 0.82
The effects of aging and chronic fluoxetine treatment on circadian rhythms and suprachiasmatic nucleus expression of neuropeptide genes and 5-HT1B receptors. Eur J Neurosci (2010) 0.81
Animal models of obsessive-compulsive disorder: utility and limitations. Neuropsychiatr Dis Treat (2015) 0.78
Effect of aripiprazole, risperidone, and olanzapine on the acoustic startle response in Japanese chronic schizophrenia. Psychopharmacology (Berl) (2010) 0.77
Effects of chronic fluoxetine treatment on serotonin 1B receptor-induced deficits in delayed alternation. Psychopharmacology (Berl) (2013) 0.77
Serotonergic involvement in the amelioration of behavioral abnormalities in dopamine transporter knockout mice by nicotine. Neuropharmacology (2012) 0.76
Using mice to model Obsessive Compulsive Disorder: From genes to circuits. Neuroscience (2015) 0.76
PREPULSE INHIBITION DEFICITS ONLY IN FEMALES WITH OBSESSIVE-COMPULSIVE DISORDER. Depress Anxiety (2016) 0.75
OCD is associated with an altered association between sensorimotor gating and cortical and subcortical 5-HT1b receptor binding. J Affect Disord (2016) 0.75
Clinically effective OCD treatment prevents 5-HT1B receptor-induced repetitive behavior and striatal activation. Psychopharmacology (Berl) (2015) 0.75
Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet (2006) 6.27
Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) (2001) 5.67
Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) (2001) 4.52
Effects of chronic fluoxetine in animal models of anxiety and depression. Neuropsychopharmacology (2004) 3.17
Presidential Address, 1974. The more or less startling effects of weak prestimulation. Psychophysiology (1975) 2.76
Enhanced aggressive behavior in mice lacking 5-HT1B receptor. Science (1994) 2.32
Brain anatomy and sensorimotor gating in Asperger's syndrome. Brain (2002) 2.26
Serotonin transporter missense mutation associated with a complex neuropsychiatric phenotype. Mol Psychiatry (2003) 2.12
Altered depression-related behaviors and functional changes in the dorsal raphe nucleus of serotonin transporter-deficient mice. Biol Psychiatry (2003) 1.94
A preliminary assessment of sensorimotor gating in patients with obsessive compulsive disorder. Biol Psychiatry (1993) 1.52
A novel, putative gain-of-function haplotype at SLC6A4 associates with obsessive-compulsive disorder. Hum Mol Genet (2007) 1.39
Impaired prepulse inhibition of acoustic startle in obsessive-compulsive disorder. Biol Psychiatry (2005) 1.30
Altered expression and functions of serotonin 5-HT1A and 5-HT1B receptors in knock-out mice lacking the 5-HT transporter. Eur J Neurosci (2000) 1.29
A single amino-acid difference confers major pharmacological variation between human and rodent 5-HT1B receptors. Nature (1992) 1.26
Pharmacological differentiation and characterization of 5-HT1A, 5-HT1B, and 5-HT1C binding sites in rat frontal cortex. J Neurochem (1986) 1.20
5-hydroxytryptamine1B receptors block the GABAB synaptic potential in rat dopamine neurons. J Neurosci (1992) 1.17
The neural substrates of sensorimotor gating of the startle reflex: a review of recent findings and their implications. J Psychopharmacol (1992) 1.13
A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiatry (1993) 1.13
Behavioral organization is independent of locomotor activity in 129 and C57 mouse strains. Brain Res (1999) 1.10
8-OH-DPAT as a 5-HT7 agonist: phase shifts of the circadian biological clock through increases in cAMP production. Neuropharmacology (2004) 1.08
Multiple limbic regions mediate the disruption of prepulse inhibition produced in rats by the noncompetitive NMDA antagonist dizocilpine. J Neurosci (1998) 1.04
Effects of strain and serotonergic agents on prepulse inhibition and habituation in mice. Neuropharmacology (2000) 1.02
Effects of serotonergic and noradrenergic antidepressants on auditory startle response in patients with major depression. Psychopharmacology (Berl) (2004) 1.01
Serotonin1B receptor modulation of startle reactivity, habituation, and prepulse inhibition in wild-type and serotonin1B knockout mice. Psychopharmacology (Berl) (1997) 0.98
The role of D1 and D2 dopamine receptors in oral stereotypy induced by dopaminergic stimulation of the ventrolateral striatum. Neuroscience (1990) 0.97
Support for the association between the rare functional variant I425V of the serotonin transporter gene and susceptibility to obsessive compulsive disorder. Mol Psychiatry (2005) 0.97
The relationship between repetitive behaviors and growth hormone response to sumatriptan challenge in adult autistic disorder. Neuropsychopharmacology (2000) 0.97
Multiple serotonin receptor subtypes modulate prepulse inhibition of the startle response in rats. Neuropharmacology (1994) 0.96
The effects of the 5-HT(2C) receptor antagonist SB242084 on locomotor activity induced by selective, or mixed, indirect serotonergic and dopaminergic agonists. Psychopharmacology (Berl) (2006) 0.95
Tolerance and cross-tolerance to the activating effects of 3,4-methylenedioxymethamphetamine and a 5-hydroxytryptamine1B agonist. J Pharmacol Exp Ther (1992) 0.93
Quantitative assessment of the microstructure of rat behavior: I, f(d), the extension of the scaling hypothesis. Psychopharmacology (Berl) (1993) 0.90
Serotonergic dissection of obsessive compulsive symptoms: a challenge study with m-chlorophenylpiperazine and sumatriptan. Neuropsychobiology (2004) 0.89
Is the 5-HT(1Dbeta) receptor gene implicated in the pathogenesis of obsessive-compulsive disorder? Am J Psychiatry (2000) 0.88
Evidence that RU 24969-induced locomotor activity in C57/B1/6 mice is specifically mediated by the 5-HT1B receptor. Br J Pharmacol (1993) 0.86
A single amino acid difference accounts for the pharmacological distinctions between the rat and human 5-hydroxytryptamine1B receptors. J Neurochem (1993) 0.86
Single photon emission computed tomography of the brain with Tc-99m HMPAO during sumatriptan challenge in obsessive-compulsive disorder: investigating the functional role of the serotonin auto-receptor. Prog Neuropsychopharmacol Biol Psychiatry (1999) 0.86
Phencyclidine-induced deficits in prepulse inhibition of startle are blocked by prazosin, an alpha-1 noradrenergic antagonist. J Pharmacol Exp Ther (1997) 0.86
Chronic fluoxetine treatment selectively uncouples raphe 5-HT(1A) receptors as measured by [(35)S]-GTP gamma S autoradiography. Br J Pharmacol (2002) 0.86
Serotonin microinfusion into the ventral tegmental area increases accumbens dopamine release. Brain Res Bull (1989) 0.83
Zolmitriptan (a 5-HT1B/1D receptor agonist with central action) does not increase symptoms in obsessive compulsive disorder. Psychopharmacology (Berl) (2000) 0.83
Sumatriptan, 5-HT(1D) receptors and obsessive-compulsive disorder. Eur Neuropsychopharmacol (2001) 0.83
Serotonin1B receptor activation mimics behavioral effects of presynaptic serotonin release. Neuropsychopharmacology (1993) 0.83
GR 127935 reduces basal locomotor activity and prevents RU 24969-, but not D-amphetamine-induced hyperlocomotion, in the Wistar-Kyoto hyperactive (WKHA) rat. Psychopharmacology (Berl) (1999) 0.82
Serotonin-1D hypothesis of obsessive-compulsive disorder: an update. J Clin Psychiatry (2004) 0.81
Distinct functions for dopamine and serotonin in locomotor behaviour: evidence using the 5-HT1 agonist RU 24969 in globus pallidus-lesioned rats. Neurosci Lett (1986) 0.81
Effects of acute treatment with antidepressant drugs on sensorimotor gating deficits in rats. Psychopharmacology (Berl) (2004) 0.81
Increased growth hormone response to sumatriptan challenge in adult autistic disorders. Psychiatry Res (2000) 0.81
Sumatriptan (5-HT1D receptor agonist) does not exacerbate symptoms in obsessive compulsive disorder. Psychopharmacology (Berl) (1998) 0.80
DNA variation and psychopharmacology of the human serotonin receptor 1B (HTR1B) gene. Pharmacogenomics (2002) 0.80
Motor effects of GABA(A) antagonism in globus pallidus: studies of locomotion and tremulous jaw movements in rats. Psychopharmacology (Berl) (2003) 0.79
Dopamine release in the nucleus accumbens and latent inhibition in the rat following microinjections of a 5-HT1B agonist into the dorsal subiculum: implications for schizophrenia. J Psychopharmacol (1998) 0.79
5-HT1B receptor modulation of prepulse inhibition: recent findings in wild-type and 5-HT1B knockout mice. Ann N Y Acad Sci (1998) 0.79
5-HT3 receptor antagonism by anpirtoline, a mixed 5-HT1 receptor agonist/5-HT3 receptor antagonist. Br J Pharmacol (1995) 0.78
Evidence that the unilateral activation of 5-HT1D receptors in the substantia nigra of the guinea-pig elicits contralateral rotation. Br J Pharmacol (1991) 0.77
Sulpiride injection into the dorsal striatum increases methamphetamine-induced gnawing in rats. Eur J Pharmacol (1987) 0.77
Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell (2008) 5.93
An in vivo correlate of exercise-induced neurogenesis in the adult dentate gyrus. Proc Natl Acad Sci U S A (2007) 5.30
Adult hippocampal neurogenesis in depression. Nat Neurosci (2007) 4.79
Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice. Science (2004) 4.31
Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature (2008) 4.09
A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure. Cell (2009) 3.28
Habituation revisited: an updated and revised description of the behavioral characteristics of habituation. Neurobiol Learn Mem (2008) 3.23
Effects of chronic fluoxetine in animal models of anxiety and depression. Neuropsychopharmacology (2004) 3.17
Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron (2007) 2.98
Targeted gene expression in dopamine and serotonin neurons of the mouse brain. J Neurosci Methods (2004) 2.80
Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP. Proc Natl Acad Sci U S A (2002) 2.64
Cortical 5-HT2A receptor signaling modulates anxiety-like behaviors in mice. Science (2006) 2.49
Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat Rev Drug Discov (2012) 2.44
Recent advances in animal models of chronic antidepressant effects: the novelty-induced hypophagia test. Neurosci Biobehav Rev (2005) 2.40
Chromatin and sequence features that define the fine and gross structure of genomic methylation patterns. Genome Res (2010) 2.25
Young and excitable: the function of new neurons in the adult mammalian brain. Curr Opin Neurobiol (2005) 2.18
Experience dictates stem cell fate in the adult hippocampus. Neuron (2011) 2.18
The developmental origins of anxiety. Nat Rev Neurosci (2004) 2.17
Removing obstacles in neuroscience drug discovery: the future path for animal models. Neuropsychopharmacology (2008) 2.16
Antidepressant-induced neurogenesis in the hippocampus of adult nonhuman primates. J Neurosci (2007) 2.12
Inhibition of serotonin but not norepinephrine transport during development produces delayed, persistent perturbations of emotional behaviors in mice. J Neurosci (2008) 2.11
Behavioral effects of chronic fluoxetine in BALB/cJ mice do not require adult hippocampal neurogenesis or the serotonin 1A receptor. Neuropsychopharmacology (2007) 2.11
Altered depression-related behaviors and functional changes in the dorsal raphe nucleus of serotonin transporter-deficient mice. Biol Psychiatry (2003) 1.94
A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: implications for the neuropathology of schizophrenia. Biol Psychiatry (2006) 1.93
Stimulus-induced changes in blood flow and 2-deoxyglucose uptake dissociate in ipsilateral somatosensory cortex. J Neurosci (2008) 1.89
Genetic and hormonal factors modulate spreading depression and transient hemiparesis in mouse models of familial hemiplegic migraine type 1. J Clin Invest (2008) 1.81
Type III neuregulin-1 is required for normal sensorimotor gating, memory-related behaviors, and corticostriatal circuit components. J Neurosci (2008) 1.80
A reverse-translational study of dysfunctional exploration in psychiatric disorders: from mice to men. Arch Gen Psychiatry (2009) 1.69
Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacol Ther (2009) 1.67
Transcriptome fingerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex. J Neurosci (2003) 1.64
Shared synaptic pathophysiology in syndromic and nonsyndromic rodent models of autism. Science (2012) 1.63
Fingolimod provides long-term protection in rodent models of cerebral ischemia. Ann Neurol (2010) 1.62
How stress and fluoxetine modulate serotonin 2C receptor pre-mRNA editing. J Neurosci (2005) 1.57
Adult hippocampal neurogenesis as target for the treatment of depression. CNS Neurol Disord Drug Targets (2007) 1.56
Dopamine modulates cell cycle in the lateral ganglionic eminence. J Neurosci (2003) 1.50
Deficits in prepulse inhibition and habituation in never-medicated, first-episode schizophrenia. Biol Psychiatry (2003) 1.48
Essential role for orbitofrontal serotonin 1B receptors in obsessive-compulsive disorder-like behavior and serotonin reuptake inhibitor response in mice. Biol Psychiatry (2011) 1.46
Microemboli may link spreading depression, migraine aura, and patent foramen ovale. Ann Neurol (2010) 1.45
Necessity of hippocampal neurogenesis for the therapeutic action of antidepressants in adult nonhuman primates. PLoS One (2011) 1.45
Neurodevelopmental origins of depressive disorders. Curr Opin Pharmacol (2006) 1.44
Mechanism of the 5-hydroxytryptamine 2A receptor-mediated facilitation of synaptic activity in prefrontal cortex. Proc Natl Acad Sci U S A (2007) 1.42
Sphingosine-1-phosphate induces proliferation and morphological changes of neural progenitor cells. J Neurochem (2004) 1.41
Studies in genetically modified mice suggest novel mechanisms of mood regulation. Biol Psychiatry (2010) 1.38
Arrest of adult hippocampal neurogenesis in mice impairs single- but not multiple-trial contextual fear conditioning. Behav Neurosci (2010) 1.38
Neuroscience. Is more neurogenesis always better? Science (2007) 1.36
Differential contributions of dopamine D1, D2, and D3 receptors to MDMA-induced effects on locomotor behavior patterns in mice. Neuropsychopharmacology (2006) 1.33
Perception measurement in clinical trials of schizophrenia: promising paradigms from CNTRICS. Schizophr Bull (2008) 1.32
Brain injury and neurofunctional deficit in neonatal mice with hypoxic-ischemic encephalopathy. Behav Brain Res (2003) 1.31
A reverse-translational approach to bipolar disorder: rodent and human studies in the Behavioral Pattern Monitor. Neurosci Biobehav Rev (2007) 1.29
Characterization of neurophysiologic and neurocognitive biomarkers for use in genomic and clinical outcome studies of schizophrenia. PLoS One (2012) 1.28
Migraine mutations increase stroke vulnerability by facilitating ischemic depolarizations. Circulation (2011) 1.28
Valproate attenuates hyperactive and perseverative behaviors in mutant mice with a dysregulated dopamine system. Biol Psychiatry (2003) 1.28
Corticotropin-releasing factor receptors CRF1 and CRF2 exert both additive and opposing influences on defensive startle behavior. J Neurosci (2004) 1.26
Differential effects of direct and indirect dopamine agonists on prepulse inhibition: a study in D1 and D2 receptor knock-out mice. J Neurosci (2002) 1.24
5-HT(2A) and 5-HT(2C) receptors exert opposing effects on locomotor activity in mice. Neuropsychopharmacology (2009) 1.24
FGF-2 regulates neurogenesis and degeneration in the dentate gyrus after traumatic brain injury in mice. J Clin Invest (2003) 1.24
Multicolored stain-free histopathology with coherent Raman imaging. Lab Invest (2012) 1.22
The serotonergic system and anxiety. Neuromolecular Med (2004) 1.22
Assessment of murine startle reactivity, prepulse inhibition, and habituation. Curr Protoc Neurosci (2003) 1.21
Anxiety as a developmental disorder. Neuropsychopharmacology (2007) 1.21
Prepulse inhibition and genetic mouse models of schizophrenia. Behav Brain Res (2009) 1.20
The 5-choice continuous performance test: evidence for a translational test of vigilance for mice. PLoS One (2009) 1.20
The quantitative assessment of motor activity in mania and schizophrenia. J Affect Disord (2010) 1.18
Neural correlates of tactile prepulse inhibition: a functional MRI study in normal and schizophrenic subjects. Psychiatry Res (2003) 1.17
Impaired sensorimotor gating in unmedicated adults with obsessive-compulsive disorder. Neuropsychopharmacology (2012) 1.17
Harnessing cognitive neuroscience to develop new treatments for improving cognition in schizophrenia: CNTRICS selected cognitive paradigms for animal models. Neurosci Biobehav Rev (2013) 1.16
S1P3 receptors mediate the potent constriction of cerebral arteries by sphingosine-1-phosphate. Eur J Pharmacol (2003) 1.16
A fMRI investigation of startle gating deficits in schizophrenia patients treated with typical or atypical antipsychotics. Int J Neuropsychopharmacol (2006) 1.15
The relationship of age to prepulse inhibition and habituation of the acoustic startle response. Biol Psychol (2003) 1.15
GBR 12909 administration as a mouse model of bipolar disorder mania: mimicking quantitative assessment of manic behavior. Psychopharmacology (Berl) (2009) 1.14
Genetic approaches to the study of anxiety. Annu Rev Neurosci (2004) 1.13
Haloperidol differentially modulates prepulse inhibition and p50 suppression in healthy humans stratified for low and high gating levels. Neuropsychopharmacology (2007) 1.13
Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia. Biochem Pharmacol (2013) 1.13
The mouse attentional-set-shifting task: a method for assaying successful cognitive aging? Cogn Affect Behav Neurosci (2010) 1.11
Distribution of sphingosine kinase activity and mRNA in rodent brain. J Neurochem (2007) 1.11
Role of corticotropin releasing factor (CRF) receptors 1 and 2 in CRF-potentiated acoustic startle in mice. Psychopharmacology (Berl) (2003) 1.11
Dentate gyrus neurogenesis and depression. Prog Brain Res (2007) 1.10
Transcription factor SP4 is a susceptibility gene for bipolar disorder. PLoS One (2009) 1.10
Sensitization and habituation of the acoustic startle reflex in patients with schizophrenia. Psychiatry Res (2004) 1.10
Late measures of brain injury after neonatal hypoxia-ischemia in mice. Stroke (2004) 1.10
5-HT(2A) receptors: location and functional analysis in intestines of wild-type and 5-HT(2A) knockout mice. Am J Physiol Gastrointest Liver Physiol (2002) 1.09
Enhanced subcortical spreading depression in familial hemiplegic migraine type 1 mutant mice. J Neurosci (2011) 1.07
Stability of the acoustic startle reflex, prepulse inhibition, and habituation in schizophrenia. Schizophr Res (2002) 1.06
Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology (2011) 1.06
Dopamine D1 rather than D2 receptor agonists disrupt prepulse inhibition of startle in mice. Neuropsychopharmacology (2003) 1.05
Prepulse inhibition of the acoustically evoked startle reflex in patients with an acute schizophrenic psychosis--a longitudinal study. Eur Arch Psychiatry Clin Neurosci (2004) 1.05
Animal models of schizophrenia. Curr Top Behav Neurosci (2010) 1.04
Developing predictive animal models and establishing a preclinical trials network for assessing treatment effects on cognition in schizophrenia. Schizophr Bull (2005) 1.04
Predictive animal models of mania: hits, misses and future directions. Br J Pharmacol (2011) 1.04
Autism and increased paternal age related changes in global levels of gene expression regulation. PLoS One (2011) 1.03
Foxa1 and foxa2 are required for the maintenance of dopaminergic properties in ventral midbrain neurons at late embryonic stages. J Neurosci (2013) 1.03